Search Result

Results for "

cyclin-dependent-kinases-cdks

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (40) Akt (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (9) Autophagy (1) Bcl-2 Family (1) Caspase (1) CFTR (1) DYRK (1) ERK (1) FGFR (1) FLT3 (1) GSK-3 (5) HDAC (1) JNK (2) Ligands for Target Protein for PROTAC (1) PARP (1) PKC (2) PROTACs (1) TOPK (2) VEGFR (1) Wnt (1)
By Research Areas:	Cancer (36) Cardiovascular Disease (2) Infection (3) Inflammation/Immunology (2) Neurological Disease (2)

Inhibitors & Agonists

Natural
Products

Targets Recommended: CDK Cyclin G-associated Kinase (GAK) CDKL Apical Sodium-Dependent Bile Acid Transporter CaMK PKG SNIPERs DNA-PK VDAC SGLT PDK-1 Pyruvate Oxidase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145599

Tanuxiciclib	CDK	Cancer
Tanuxiciclib is a *cyclin dependent kinase (CDK)* inhibitor .

HY-145599A

Tanuxiciclib trihydrochloride	CDK	Cancer
Tanuxiciclib trihydrochloride is a *cyclin dependent kinase (CDK)* inhibitor .

HY-145563

Eciruciclib	CDK	Cancer
Eciruciclib is an antineoplastic and potent *cyclin dependent kinase (CDK)* inhibitor .

HY-114177A

(S)-Ebvaciclib (S)-PF-06873600	CDK	Cancer
(S)-PF-06873600 it the S enantiomer of PF-06873600. PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK).

HY-147386

CDK-IN-10	CDK	Cancer
CDK-IN-10 (example 54) is a cyclin dependent kinase (CDK) inhibitor that can be used in cancer research .

HY-114248

AGM-130	CDK	Cancer
AGM-130 is a *cyclin-dependent kinase* (CDK) inhibitor. AGM-130 exhibits antitumor activity .

HY-114093

AG-12275	CDK	Cancer
AG-12275 is a *cyclin-dependent kinase* (CDK) inhibitor. AG-12275 can be used for the research of cancer .

HY-170442

CDK2-IN-37	CDK	Cancer
CDK2-IN-37 (COMPOUND 2) is a cyclin-dependent kinase (CDK2) inhibitor with anti-cancer activity .

HY-163170

FMF-04-159-R	CDK	Cancer
FMF-04-159-R is a cyclin-dependent kinase CDK14 and CDK16 inhibitor with IC₅₀ values of 5.9 and 139.1 nM .

HY-160941

CDK2-IN-29	CDK	Cancer
CDK2-IN-29 (Compound 13q) is an inhibitor for *cyclin-dependent kinase* (CDK), with IC₅₀ of 96 nM and 360 nM, for CDK 2 and CDK 4, respectively .

HY-162785

XC219	CDK	Infection
XC219 (compound 43) is a cyclin-dependent kinase CDK) inhibitor, that covalently binds to CDK active site Lys. XC219 can be used in antifungal research .

HY-124321

Metralindole hydrochloride	CDK	Cancer
Metralindole hydrochloride is an inhibitor of human cyclin-dependent kinase CDK2 and human protein kinase CK2 holoenzyme. Metralindole hydrochloride shows good potential as a non-small cell lung cancer inhibitor .

HY-124321A

Metralindole	CDK	Cancer
Metralindole is an inhibitor of human cyclin-dependent kinase CDK2 and human protein kinase CK2 holoenzyme. Metralindole shows good potential as a non-small cell lung cancer inhibitor .

HY-13914

Roniciclib BAY 1000394	CDK	Cancer
Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC₅₀s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.

HY-118902

Aloisine B	CDK	Others
Aloisine B (compound 9) is a cyclin-dependent kinase (CDK) inhibitor. Aloisine B inhibits cell proliferation by arresting cells in both G1 and G2 via competing with ATP-binding pocket .

HY-114779

N9-Isopropylolomoucine	CDK	Cancer
N9-Isopropylolomoucine is a mitotic cyclin dependent kinase (CDK) inhibitor. N9-Isopropylolomoucine targets CCNB 1/CDK1 and can be used for cancer research .

HY-151371

CDK8-IN-10	CDK	Cancer
CDK8-IN-10 (compound 2) is a potent, selective *cyclin-dependent kinase (CDK8)* inhibitor with an IC₅₀ value of 8.25 nM. CDK8-IN-10 can be used for research of cancer .

HY-19718

OTS964	TOPK CDK Apoptosis	Cancer
OTS964 is an orally active, high affinity and selective TOPK inhibitor with an IC₅₀ of 28 nM . OTS964 is also a potent inhibitor of the cyclin-dependent kinase CDK11, which binds to CDK11B with a K_d of 40 nM .

HY-149261

H1k	Autophagy CDK	Cancer
H1k, a Eudistomin Y derivative, is a lysosome-targeted antiproliferation agent. H1k increases the autophagy signal and downregulate the expression of cyclin-dependent kinase (CDK1) and cyclin B1. H1k can be used in research of cancer .

HY-114177

Ebvaciclib 4 Publications Verification PF-06873600	CDK	Cancer
PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with K_i values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity .

HY-12467

OTS964 hydrochloride Maximum Cited Publications 10 Publications Verification	TOPK CDK Apoptosis	Cancer
OTS964 hydrochloride is an orally active, high affinity and selective TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor with an IC₅₀ of 28 nM . OTS964 hydrochloride is also a potent inhibitor of the cyclin-dependent kinase CDK11, which binds to CDK11B with a K_d of 40 nM .

HY-161768

VCC972839:01	CDK Apoptosis	Cancer
VCC972839:01 is an inhibitor for *cyclin dependent kinase* (CDK9), with IC₅₀ of 7 nM. VCC972839:01 inhibits the cell viability of SCLC cells in nanomolar levels. VCC972839:01 induces apoptosis through an intrinsic pathway. VCC972839:01 exhibits antitumor activity in mouse model .

HY-116204

SKLB70326	Caspase CDK Apoptosis Bcl-2 Family PARP	Others
SKLB70326 is a small molecule inhibitor of cell cycle progression that induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cells. SKLB70326 is involved in downregulating cyclin-dependent kinase (CDK) 2, CDK4, and CDK6, while also activating PARP, caspase-3, caspase-9, and Bax, and downregulating Bcl-2.

HY-157647

1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC PC(18:0/22:4)	CDK Apoptosis	Cancer
1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC (PC(18:0/22:4)) is an inhibitor of cyclin-dependent kinases (CDKs). 1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC induces apoptosis and inhibits the growth of various cancer cell lines .

HY-50892

(Rac)-Roscovitine (Rac)-Seliciclib; (Rac)-CYC202	CDK Apoptosis	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
(Rac)-Roscovitine ((Rac)-Seliciclib) is a selective cyclin-dependent kinases (CDKs) inhibitor. (Rac)-Roscovitine binds to the active sites of CDKs competitively with ATP, inhibiting the phosphorylation activity of CDKs. (Rac)-Roscovitine induces apoptosis in cancer cells. (Rac)-Roscovitine is promising for research of cancers or other diseases associated with CDK dysregulation, such as neurodegenerative diseases, cardiac disorders, viral and protozoan infections, glomerulonephritis, and chronic inflammation .

HY-16559A

Riviciclib P276-00 free base	CDK	Cancer
Riviciclib (P276-00 free base) is a potent *cyclin-dependent kinase (CDK)* inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib shows antitumor activity on cisplatin-resistant cells .

HY-16559

Riviciclib hydrochloride 3 Publications Verification P276-00	CDK Apoptosis	Cancer
Riviciclib hydrochloride (P276-00) is a potent *cyclin-dependent kinase (CDK)* inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .

HY-N12625

(R)-(+)-O-Demethylbuchenavianine	CDK DYRK GSK-3	Cancer
(R)-(+)-O-Demethylbuchenavianine is an inhibitor for Cyclin-dependent kinases (CDK). (R)-(+)-O-Demethylbuchenavianine inhibits CDK1, CDK5, glycogen synthase kinase-3 (GSK3), cdc2-like kinase (CLK1) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), with IC₅₀s of 1.1, 0.95, >10, >10 and >10 μM, respectively .

HY-145394

CDK7-IN-6	CDK	Cancer
CDK7-IN-6 is a potent and selective cyclin-dependent kinase (CDK7) inhibitor (IC₅₀≤100 nM), extracted from patent WO2019197549 A1, compound 210. CDK7-IN-6 is > 200-fold selective for CDK7 over CDK1, CDK2, and CDK5. CDK7-IN-6 can be used for the research of cancer .

HY-147409

Ulecaciclib	CDK	Cancer
Ulecaciclib is an orally activitive inhibitor of *cyclin-dependent kinase* (CDK), with K_i values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics .

HY-15275

BMS-265246 1 Publications Verification	CDK Angiotensin-converting Enzyme (ACE)	Infection Cardiovascular Disease Cancer
BMS-265246 is a potent and selective *cyclin-dependent kinase* CDK1 and CDK2 inhibitor, with IC₅₀ values of 6 and 9 nM, respectively. BMS-265246 inhibits CHI3L1 (chitinase 3-like-1) stimulation of ACE2 (angiotensin converting enzyme 2) and SPP (viral spike protein priming proteases). BMS-265246 can be used for ovarian cancer and COVID-19 research .

HY-161709

*FLT3/CDKs* ligand-1**	Ligands for Target Protein for PROTAC FLT3 CDK	Cancer
FLT3/CDKs ligand-1 (Compound 14) is a ligand for target protein, which promotes the degradation of cyclin-dependent kinase (CDK) and the FMS-like tyrosine kinase 3 (FLT3), inhibits FLT3/CDK related proliferations and survivals of leukemia cells. LT3/CDKs ligand-1 can be used for synthesis of PROTAC FLT3/CDKs degrader-1 (HY-161708) .

HY-169075

CDK/HDAC-IN-4	HDAC CDK Apoptosis	Cancer
CDK/HDAC-IN-4 is a high selective dual cyclin-dependent kinase (CDK)/histone deacetylase (HDAC) inhibitor with IC₅₀ values of 88.4 and 168.9 nM, respectively. CDK/HDAC-IN-4 exhibits antiproliferative capacities against hematological and solid tumor cells. CDK/HDAC-IN-4 also induces MV-4-11 cell Apoptosis and S cell cycle arrests. CDK/HDAC-IN-4 possesses a significant antitumor potency in the MV-4-11 xenograft model .

HY-13661

7-Hydroxystaurosporine 1 Publications Verification UCN-01; KRX-0601	Akt PKC CDK Apoptosis	Cancer
7-Hydroxystaurosporine (UCN-01) is a synthetic derivative of Staurosporine (HY-15141) with antitumor activity. 7-hydroxystaurosporine inhibits serine/threonine kinase AKT and calcium-dependent *protein kinase* C** activity. 7-hydroxystaurosporine also activates indirectly cyclin-dependent kinases (CDKs). 7-hydroxystaurosporine arrests tumor cells in the G1/S of the cell cycle and prevents nucleotide excision repair by inhibiting the G2 checkpoint kinase chk1, resulting in apoptosis .

HY-111932

Indirubin-5-sulfonate	CDK GSK-3	Cancer
Indirubin-5-sulfonate is a *cyclin-dependent kinase (CDK)* inhibitor, with IC₅₀ values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively . Indirubin-5-sulfonate also shows inhibitory activity against GSK-3β .

HY-11009

CGP60474 5+ Cited Publications	CDK PKC	Cancer
CGP60474, a highly potent anti-endotoxemic agent, is a potent *cyclin-dependent kinase (CDK)* inhibitor (IC₅₀ values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor .

HY-139254

Indirubin-3′-oxime IDR3O; I3O	CDK GSK-3 JNK Wnt	Neurological Disease
Indirubin-3′-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC₅₀s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes .

HY-134303

CST651 PROTAC CDK4/6 degrader 34	PROTACs CDK	Cancer
CST651 (PROTAC CDK4/6 degrader 34) is a selective cyclin dependent kinase CDK4/6 PROTAC degrader. CST651 can degrade CDK4 and CDK6 in MM.1S cells with DC₅₀ values of 20 and 5.1 nM. CST651 can inhibit cancer cells proliferation and migration. CST651 can be used for the research of cancer, such as acute lymphoblastic leukemia . (Structure Note: Pink: CDK4/6 ligand (HY-50767); Blue: VHL ligand (HY-125905); Black: linker (HY-W017440))

HY-141685

3-Methylthienyl-carbonyl-JNJ-7706621	CDK GSK-3 VEGFR FGFR	Cancer
3-Methylthienyl-carbonyl-JNJ-7706621 is a potent and selective inhibitor of *cyclin-dependent kinase (CDK), with IC₅₀s of 6.4 nM and 2 nM for CDK1/cyclin* B and CDK2/cyclin A, respectively. 3-Methylthienyl-carbonyl-JNJ-7706621 also shows potent inhibition of GSK-3 (IC₅₀=0.041 μM) and modest potency against CDK4, VEGF-R2, and FGF-R2 (IC₅₀=0.11, 0.13, 0.22 μM, respectively). 3-Methylthienyl-carbonyl-JNJ-7706621 can be used for the research of cancer .

HY-112363

Aloisine A RP107	CDK GSK-3 ERK JNK CFTR	Inflammation/Immunology Cancer
Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC₅₀s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC₅₀=0.5 μM) and GSK-3β (IC₅₀=1.5 μM). Aloisine A stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Aloisine A has the potential for CFTR-related diseases, including cystic fibrosis research .

(R)-(+)-O-Demethylbuchenavianine	Alkaloids Flavonoids Flavones Other Alkaloids Buchenavia macrophylla Spruce ex Eichler Combretaceae Source classification Plants	CDK DYRK GSK-3
(R)-(+)-O-Demethylbuchenavianine is an inhibitor for Cyclin-dependent kinases (CDK). (R)-(+)-O-Demethylbuchenavianine inhibits CDK1, CDK5, glycogen synthase kinase-3 (GSK3), cdc2-like kinase (CLK1) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), with IC₅₀s of 1.1, 0.95, >10, >10 and >10 μM, respectively .

1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC PC(18:0/22:4)	Structural Classification Source classification Endogenous metabolite Lipid	CDK Apoptosis
1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC (PC(18:0/22:4)) is an inhibitor of cyclin-dependent kinases (CDKs). 1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC induces apoptosis and inhibits the growth of various cancer cell lines .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

cyclin-dependent-kinases-cdks

Inhibitors & Agonists

NaturalProducts

Natural
Products